

# An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

NCT07220603

---

Status	RECRUITING
Phase	Phase 2
Sponsor	PepGen Inc
Enrollment	48 participants

## Key Eligibility Criteria

---

### Inclusion (1)

- Participant has completed a prior study with PGN-EDODM1

### Exclusion (2)

- Abnormal laboratory tests at screening considered clinically significant by the Investigator
- Use of an investigational drug (other than PGN-EDODM1), device, or product, within 30 days or 5 half-lives of the study drug (whichever is longer) prior to study entry

## Locations (3 total)

---

University of Calgary, Calgary, Alberta, Canada  
Ottawa Hospital Research Institute, Ottawa, Ontario, Canada  
CIUSSS du Saguenay-Lac-Saint-Jean, Saguenay, Canada